On Demand ACAAI 2022 Annual Scientific Meeting General Sessions

Cost: $345 for College members, $425 for non-members.

You can earn up to 56.75 AMA PRA Category 1 Credits™. This collection covers sessions from Friday, Saturday, Sunday, and Monday.

Sessions included:

Integrative Modalities in Allergy & Immunology Practice
Atopic Dermatitis: Triggers, Mimics and Treatments
Real World Alternatives to Traditional SCIT
Lessons Learned on Primary Prevention of Food Allergy
Looking for Zebras in Diagnosing PIDD
Be Aware of the Copycat -- Asthma Mimickers
Evaluation and Management of non-IgE Food Allergy
Presidential Plenary - Food Allergy - Where Are We in 2022?
Drug Hypersensitivity Reactions in 2022: What Should We Know?
Physician Health, Wellness and Burnout
Decision Thresholds for Management Recommendations
EAACI - Novel Insights into the Endotype of Allergic Asthma
Anaphylaxis Practice Parameter Update
The Asthma Patient: What Would You Do?
Editor's Pick - Best Articles from Annals of Allergy, Asthma and Immunology
Hot Topics and Practical Pearls in Dermatology
Management of Primary Immunodeficiency Beyond Immunoglobulin Replacement
Plenary - Practicing Allergy/Immunology into the Future
Mastering Biologics Used in Atopic Conditions
7 for 11 - Hot Topics in Pediatrics A&I - A Joint Presentation from AAP-SOAI & ACAAI
Managing CRSwNP in the Office: Putting it all Together
Updates on Urticaria and Advice in Angioedema
Introductory Course in Rhinolaryngoscopy - Didactic
Allergen Mixing in the Allergist's Office - Session One: The Changing Environment in Allergy and Immunology Extract Mixing
Jeopardy: What's That Rash, Doctor? Dermatology
Coding and Government Relations
Addressing the Mental Health Impact on Patients, Parents, Families
In the News at ABAI
Utilizing Genetic Testing to Manage Immunodeficiency
Allergen Mixing in the Allergists Office - Session Two: The Compliant Mixing Room
Breastfeeding and Maternal Diet in Eczema and Food Allergies
Plenary - Implementing New Guidelines Into Practice
World Allergy Organization Forum: New Approaches to Drug Allergies
How Do I Know if Allergy Shots are Working?
Advances in Food Allergy Immunotherapy
Aspirin Desensitization vs Biologic Therapy for Patients with AERD
The Management of COVID for the Allergist / Immunologist
Hybrid Care: The Use of Remote Patient Monitoring in Clinical Practice
Infections, Microbiome and Bacteriotherapies in Atopic Dermatitis
Treatment of Non-Th2 Asthma

Release Date: 12/5/2022
Expiration Date: 12/4/2025

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 55.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

Practicing allergist/immunologists
Academic allergists including training program and division directors
Allergy/immunology fellows in training
Physician assistants and advanced practice nurses
Allied health professionals
Primary care physicians and other medical professionals

Learning Objectives

At the conclusion of this activity, participants should be able to:

Identify major advances in key areas of cutting-edge research in immunologic mechanisms and allergic responses.
Demonstrate knowledge of basic processes linking molecular and cellular biology and genetics with allergic pathophysiology and immunodeficiency.
Translate emerging clinical science principles to clinical practice in patients with allergic and immunologic diseases.
Evaluate and implement state-of-the-art diagnostic and therapeutic strategies for treating patients with allergic and immunologic diseases.
Explain the impact of environmental exposures and external influences on patients with allergic disorders.
Recognize emerging trends in the prevalence of allergic and immunologic disorders and discuss their impact on public health.
Evaluate the impact of new diagnostic and therapeutic strategies on health care costs and outcomes.
Discuss processes, tools and technologies for the efficient allergy and immunology practice.

Additional information

Disclosure:

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

•   Advertising, marketing, or communication firms whose clients are ineligible companies
•   Bio-medical startups that have begun a governmental regulatory approval process
•   Compounding pharmacies that manufacture proprietary compounds
•   Device manufacturers or distributors
•   Diagnostic labs that sell proprietary products
•   Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•   Manufacturers of health-related wearable products
•   Pharmaceutical companies or distributors
•   Pharmacy benefit managers
•   Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.